RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BridgeBio Pharma Stock

BridgeBio Pharma Net Income 2025

BridgeBio Pharma Net Income

-598.27 M USD

Ticker

BBIO

ISIN

US10806X1028

WKN

A2PLX7

In 2025, BridgeBio Pharma's profit amounted to -598.27 M USD, a 11.67% increase from the -535.76 M USD profit recorded in the previous year.

The BridgeBio Pharma Net Income history

YEARNET INCOME (undefined USD)
2030e1.58
2029e1.1
2028e0.41
2027e-0
2026e-0.39
2025e-0.6
2024-0.54
2023-0.64
2022-0.48
2021-0.56
2020-0.45
2019-0.26
2018-0.13
2017-0.03

BridgeBio Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BridgeBio Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BridgeBio Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BridgeBio Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BridgeBio Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BridgeBio Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BridgeBio Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BridgeBio Pharma’s growth potential.

BridgeBio Pharma Revenue, EBIT and net profit per share

DateBridgeBio Pharma RevenueBridgeBio Pharma EBITBridgeBio Pharma Net Income
2030e3.33 B undefined0 undefined1.58 B undefined
2029e2.42 B undefined973.87 M undefined1.1 B undefined
2028e1.91 B undefined593.45 M undefined408.06 M undefined
2027e1.26 B undefined110.07 M undefined-1.66 M undefined
2026e706.45 M undefined-338.58 M undefined-389.89 M undefined
2025e457.84 M undefined-469.06 M undefined-598.27 M undefined
2024221.9 M undefined-577.37 M undefined-535.76 M undefined
20239.3 M undefined-599.44 M undefined-643.2 M undefined
202277.65 M undefined-468.43 M undefined-481.18 M undefined
202169.72 M undefined-576.63 M undefined-562.54 M undefined
20208.25 M undefined-474.48 M undefined-448.72 M undefined
201940.56 M undefined-264.24 M undefined-260.59 M undefined
20180 undefined-183.66 M undefined-130.75 M undefined
20170 undefined-43.86 M undefined-30.57 M undefined

BridgeBio Pharma stock margins

The BridgeBio Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BridgeBio Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BridgeBio Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BridgeBio Pharma's sales revenue. A higher gross margin percentage indicates that the BridgeBio Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BridgeBio Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BridgeBio Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BridgeBio Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BridgeBio Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BridgeBio Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BridgeBio Pharma Margin History

BridgeBio Pharma Gross marginBridgeBio Pharma Profit marginBridgeBio Pharma EBIT marginBridgeBio Pharma Profit margin
2030e98.25 %0 %47.39 %
2029e98.25 %40.29 %45.55 %
2028e98.25 %31.14 %21.41 %
2027e98.25 %8.77 %-0.13 %
2026e98.25 %-47.93 %-55.19 %
2025e98.25 %-102.45 %-130.67 %
202498.25 %-260.19 %-241.44 %
202373.71 %-6,443.56 %-6,913.92 %
202295.57 %-603.26 %-619.68 %
202195.52 %-827.07 %-806.86 %
2020100 %-5,751.27 %-5,439.03 %
201993.84 %-651.48 %-642.48 %
201898.25 %0 %0 %
201798.25 %0 %0 %

BridgeBio Pharma Aktienanalyse

What does BridgeBio Pharma do?

BridgeBio Pharma Inc. is a US biotech company founded in 2015. The company is based in Palo Alto, California and specializes in researching and developing medications for rare diseases. BridgeBio's business model is based on a pipeline of rare diseases that have little or no existing treatment options. The company identifies, finances, and operates individual independent subsidiary companies with the goal of developing precision medicines for rare and genetic diseases. An important element of BridgeBio's business strategy is strategic collaboration with academic institutions and other companies to share research and development expertise. BridgeBio has various subsidiary companies, each specializing in the development of medications for a specific genetic disease. These include Eidos Therapeutics, QED Therapeutics, PellePharm, Navire Pharma, Origin Biosciences, CoA Therapeutics, Calcilytix Therapeutics, Phoenix Tissue Repair, and MyoKardia. Eidos Therapeutics is constantly searching for therapies for transthyretin-mediated amyloidosis (ATTR), a rare cardiovascular disease caused by the buildup of amyloid proteins in various parts of the body. The first FDA-approved eprodisate therapy became available in Japan in 2005, making Eidos Therapeutics one of the most promising subsidiary companies of BridgeBio. QED Therapeutics specializes in developing therapies for Gorlin syndrome and medulloblastoma, a type of brain tumor. PellePharm aims to develop a topical therapy for Gorlin syndrome that can be used to control and treat tumors and non-tumorous skin changes. Navire Pharma explores specific kinases that influence cell growth and cell death signaling pathways to identify healing methods for cancer patients. Calcilytix Therapeutics focuses on discovering a treatment solution for chronic kidney diseases, with a main focus on stopping or reducing the loss of kidney function. Overall, BridgeBio is dedicated to the development of precision medicines designed to combat the underlying genetic causes of rare diseases. The company also advances the field of precision medicine and works closely with doctors and patients to improve the diagnosis of rare diseases and optimize patient care. In 2019, BridgeBio Pharma announced a strategic partnership with the Pharmaceutical Research and Manufacturers of America (PhRMA). The goal of this collaboration is to improve awareness of rare diseases and create better access to new medications. BridgeBio hopes that the partnership will accelerate the development of therapies for rare diseases. In conclusion, BridgeBio Pharma Inc. is an innovative biotech company specializing in the development of precision medicines for the treatment of rare genetic diseases. With a business model based on collaboration with subsidiary companies and strategic partners, BridgeBio Pharma Inc. aims to revolutionize the treatment and cure of patients with rare genetic diseases. BridgeBio Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding BridgeBio Pharma's Profit Margins

The profit margins of BridgeBio Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of BridgeBio Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating BridgeBio Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

BridgeBio Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When BridgeBio Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about BridgeBio Pharma stock

How much profit has BridgeBio Pharma made this year?

BridgeBio Pharma has made -598.27 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 11.67% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does BridgeBio Pharma publish its earnings?

BridgeBio Pharma publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of BridgeBio Pharma?

The profits of BridgeBio Pharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of BridgeBio Pharma?

You can learn more about the earnings of BridgeBio Pharma by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does BridgeBio Pharma pay?

Over the past 12 months, BridgeBio Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BridgeBio Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of BridgeBio Pharma?

The current dividend yield of BridgeBio Pharma is .

When does BridgeBio Pharma pay dividends?

BridgeBio Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BridgeBio Pharma?

BridgeBio Pharma paid dividends every year for the past 0 years.

What is the dividend of BridgeBio Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BridgeBio Pharma located?

BridgeBio Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von BridgeBio Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BridgeBio Pharma from 8/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/7/2025.

When did BridgeBio Pharma pay the last dividend?

The last dividend was paid out on 8/7/2025.

What was the dividend of BridgeBio Pharma in the year 2024?

In the year 2024, BridgeBio Pharma distributed 0 USD as dividends.

In which currency does BridgeBio Pharma pay out the dividend?

The dividends of BridgeBio Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BridgeBio Pharma

Our stock analysis for BridgeBio Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BridgeBio Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.